1UC Stock Overview
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cue Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.50 |
| 52 Week High | US$4.38 |
| 52 Week Low | US$1.38 |
| Beta | 2.01 |
| 1 Month Change | -13.39% |
| 3 Month Change | -38.88% |
| 1 Year Change | -51.55% |
| 3 Year Change | -85.71% |
| 5 Year Change | -79.80% |
| Change since IPO | -84.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1UC | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.0% | -4.3% | -2.5% |
| 1Y | -51.6% | -19.4% | -0.4% |
Return vs Industry: 1UC underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: 1UC underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| 1UC volatility | |
|---|---|
| 1UC Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1UC's share price has been volatile over the past 3 months.
Volatility Over Time: 1UC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 53 | Dan Passeri | www.cuebiopharma.com |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.
Cue Biopharma, Inc. Fundamentals Summary
| 1UC fundamental statistics | |
|---|---|
| Market cap | €74.49m |
| Earnings (TTM) | -€47.66m |
| Revenue (TTM) | €5.16m |
14.0x
P/S Ratio-1.5x
P/E RatioIs 1UC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1UC income statement (TTM) | |
|---|---|
| Revenue | US$5.49m |
| Cost of Revenue | US$38.10m |
| Gross Profit | -US$32.61m |
| Other Expenses | US$18.13m |
| Earnings | -US$50.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | -593.93% |
| Net Profit Margin | -924.10% |
| Debt/Equity Ratio | 22.0% |
How did 1UC perform over the long term?
See historical performance and comparison